Figure 3.
Mean changes in BCVA (ETDRS letters) (A) and CRT (B) in patients with neovascular age‐related macular degeneration (n = 20) who received rescue medication (intravitreal ranibizumab) after prior regorafenib treatment. BCVA, best‐corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; SE, standard error